{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:34:46Z","timestamp":1793190886074,"version":"4.5.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":294,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Randy Shaver Cancer and Community Fund"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 (GM146372)"],"award-info":[{"award-number":["R01 (GM146372)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small protein ligands, such as miniproteins, have the potential to provide the efficient physiological transport and rapid clearance required for radioligand therapy. Yet, binders require single-digit nanomolar affinity for potent targeting and high stability for radiolabeling and physiological integrity. High-affinity and stable single-domain miniproteins are also modular candidates for multispecific applications in cell engagers and avid constructs. Previous work demonstrated computationally designed 40-amino acid \u03b2\u237a\u03b2\u03b2 miniproteins as effective scaffolds for ligand discovery. Herein, to yield the desired single-digit nanomolar affinity for B7-H3, an important immune regulator and cell surface antigen upregulated in numerous tumors, we used structural modeling to guide experimental evolution of the lead molecule. We performed constrained diversification at six sites on a \u03b2-sheet, structurally distinct from the originally engineered \u237a-helical paratope, as well as nine sites within the \u237a-helix, and sorted for strong binding to B7-H3 via yeast display and flow cytometry with detergent-solubilized cell lysate. Top variants discovered from this campaign yielded affinities of 8.4 and 11\u00a0nM, with the most performant variant, named \u03b2m.1, resulting in 1.2\u2009\u00b1\u20090.2\u00a0nM affinity. \u03b2m.1 had four \u03b2-sheet mutations relative to parental and Tm,app\u2009\u2265\u200991\u00b0C, with reversible unfolding. The lead variant, \u03b2m.1, putatively engages B7-H3 at the same domain I epitope as the parental lead but with improved engagement via a T27F mutation and three homologous mutations. \u03b2m.1 is a hyperstable, high-affinity miniprotein B7-H3 binder with compelling potential for radioligand therapy and multispecific applications.<\/jats:p>","DOI":"10.1093\/protein\/gzag031","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:44:54Z","timestamp":1792669494000},"source":"Crossref","is-referenced-by-count":0,"title":["Engineering a hyperstable synthetic miniprotein for B7-H3 targeting"],"prefix":"10.1093","volume":"39","author":[{"given":"Hannah K","family":"Windsor","sequence":"first","affiliation":[{"name":"Department of Chemical Engineering and Materials Science, University of Minnesota \u2013 Twin Cities , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C","family":"Ulen","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering and Materials Science, University of Minnesota \u2013 Twin Cities , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Beaudry","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Minnesota \u2013 Twin Cities , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-9463","authenticated-orcid":false,"given":"Benjamin J","family":"Hackel","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering and Materials Science, University of Minnesota \u2013 Twin Cities , Minneapolis, MN 55455 ,","place":["United States"]},{"name":"Department of Biomedical Engineering, University of Minnesota \u2013 Twin Cities , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"2026102808262949900_ref1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"2026102808262949900_ref2","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res"},{"key":"2026102808262949900_ref3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/SLA.0b013e3181f1939d","article-title":"B7\u2013H3 ligand expression by primary breast cancer and associated with regional nodal metastasis","volume":"252","author":"Arigami","year":"2010","journal-title":"Ann Surg"},{"key":"2026102808262949900_ref4","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1021\/acs.accounts.7b00186","article-title":"Miniprotein design: Past, present, and prospects","volume":"50","author":"Baker","year":"2017","journal-title":"Acc Chem Res"},{"key":"2026102808262949900_ref5","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1021\/acssynbio.3c00409","article-title":"Hyperstable synthetic mini-proteins as effective ligand scaffolds","volume":"12","author":"Blanchard","year":"2023","journal-title":"ACS Synth Biol"},{"key":"2026102808262949900_ref6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.it.2013.07.003","article-title":"B7 family checkpoint regulators in immune regulation and disease","volume":"34","author":"Ceeraz","year":"2013","journal-title":"Trends Immunol"},{"key":"2026102808262949900_ref7","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.18632\/oncotarget.7143","article-title":"A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors","volume":"7","author":"Chatterjee","year":"2016","journal-title":"Oncotarget"},{"key":"2026102808262949900_ref8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/pro.2230","article-title":"Protein\u2013protein interactions: General trends in the relationship between binding affinity and interfacial buried surface area","volume":"22","author":"Chen","year":"2013","journal-title":"Protein Sci"},{"key":"2026102808262949900_ref9","first-page":"303","volume-title":"Methods in Enzymology","author":"Chen","year":"2013"},{"key":"2026102808262949900_ref10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4939-2748-7_8","article-title":"Applications of yeast surface display for protein engineering","volume":"1319","author":"Cherf","year":"2015","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"2026102808262949900_ref11","doi-asserted-by":"publisher","first-page":"9971","DOI":"10.1021\/acs.chemrev.8b00657","article-title":"Ligation Technologies for the Synthesis of cyclic peptides","volume":"119","author":"Chow","year":"2019","journal-title":"Chem Rev"},{"key":"2026102808262949900_ref12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol"},{"key":"2026102808262949900_ref13","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2403156","article-title":"A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs","volume":"16","author":"Condado-Morales","year":"2024","journal-title":"mAbs"},{"key":"2026102808262949900_ref14","doi-asserted-by":"publisher","first-page":"10879","DOI":"10.1073\/pnas.1202866109","article-title":"General strategy for the generation of human antibody variable domains with increased aggregation resistance","volume":"109","author":"Dudgeon","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"2026102808262949900_ref15","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1093\/bioinformatics\/btq461","article-title":"Search and clustering orders of magnitude faster than BLAST","volume":"26","author":"Edgar","year":"2010","journal-title":"Bioinformatics"},{"key":"2026102808262949900_ref16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/(SICI)1096-987X(199802)19:3&lt;319::AID-JCC6&gt;3.0.CO;2-W","article-title":"Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules","volume":"19","author":"Fraczkiewicz","year":"1998","journal-title":"J Comput Chem"},{"key":"2026102808262949900_ref17","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp Mol Med"},{"key":"2026102808262949900_ref18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.sbi.2007.08.012","article-title":"Yeast surface display for protein engineering and characterization","volume":"17","author":"Gai","year":"2007","journal-title":"Curr Opin Struct Biol"},{"key":"2026102808262949900_ref19","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/JVI.72.6.5046-5055.1998","article-title":"Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions","volume":"72","author":"Gerton","year":"1998","journal-title":"J Virol"},{"key":"2026102808262949900_ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-41199-1_1","article-title":"Therapeutic potential of small molecules and engineered proteins","volume":"219","author":"Gurevich","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"2026102808262949900_ref21","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jmb.2008.06.051","article-title":"Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling","volume":"381","author":"Hackel","year":"2008","journal-title":"J Mol Biol"},{"key":"2026102808262949900_ref22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"key":"2026102808262949900_ref23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1042\/BST0350962","article-title":"Rapid discovery of protein interactions by cell-free protein technologies","volume":"35","author":"He","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"2026102808262949900_ref24","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1038\/s41467-025-59665-7","article-title":"Prolonging parathyroid hormone analog action in vitro and in vivo through peptide lipidation","volume":"16","author":"H\u00f6ppner","year":"2025","journal-title":"Nat Commun"},{"key":"2026102808262949900_ref25","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1016\/j.nucmedbio.2013.11.004","article-title":"Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with 44m\/44Sc and experimental evidence of the feasibility of an in vivo PET generator","volume":"41","author":"Huclier-Markai","year":"2014","journal-title":"Nucl Med Biol"},{"key":"2026102808262949900_ref26","doi-asserted-by":"publisher","first-page":"fuab 052","DOI":"10.1093\/femsre\/fuab052","article-title":"Phage display and other peptide display technologies","volume":"46","author":"Jaroszewicz","year":"2022","journal-title":"FEMS Microbiol Rev"},{"key":"2026102808262949900_ref27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.tips.2016.10.005","article-title":"Emerging strategies for developing next-generation protein therapeutics for cancer treatment","volume":"37","author":"Kintzing","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"2026102808262949900_ref28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.chembiol.2015.06.012","article-title":"A 45-amino-acid scaffold mined from the PDB for high-affinity ligand engineering","volume":"22","author":"Kruziki","year":"2015","journal-title":"Chem Biol"},{"key":"2026102808262949900_ref29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1021\/acscombsci.8b00010","article-title":"Constrained combinatorial libraries of Gp2 proteins enhance discovery of PD-L1 binders","volume":"20","author":"Kruziki","year":"2018","journal-title":"ACS Comb Sci"},{"key":"2026102808262949900_ref30","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3390\/ijms22042008","article-title":"Therapeutic advances in oncology","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026102808262949900_ref31","volume-title":"Aggregation, Stability, and Formulation of Human Antibody Therapeutics Academic","author":"Lowe","year":"2011"},{"key":"2026102808262949900_ref32","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/pharmaceutics13122065","article-title":"Protease-resistant peptides for targeting and intracellular delivery of therapeutics","volume":"13","author":"Lucana","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026102808262949900_ref33","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-13-1642","article-title":"Ultrasound molecular imaging in a human CD276 expression\u2013modulated murine ovarian cancer model","volume":"20","author":"Lutz","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026102808262949900_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168339","article-title":"Determinants of developability and evolvability of synthetic miniproteins as ligand scaffolds","volume":"435","author":"McConnell","year":"2023","journal-title":"J Mol Biol"},{"key":"2026102808262949900_ref35","first-page":"616","article-title":"Discovering and improving novel peptide therapeutics","volume":"8","author":"McGregor","year":"2008","journal-title":"Anti-Infect Technol"},{"key":"2026102808262949900_ref36","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/2767-9764.CRC-23-0546","article-title":"Pan-cancer interrogation of B7-H3 (CD276) as an actionable therapeutic target across human malignancies","volume":"4","author":"Miller","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026102808262949900_ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583287","article-title":"A roadmap toward the definition of actionable tumor-specific antigens","volume":"11","author":"Minati","year":"2020","journal-title":"Front Immunol"},{"key":"2026102808262949900_ref38","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.3390\/cancers17213412","article-title":"Radioligand therapy in cancer management: A global perspective","volume":"17","author":"Ninatti","year":"2025","journal-title":"Cancers"},{"key":"2026102808262949900_ref39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.nucmedbio.2012.01.002","article-title":"Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: Effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics","volume":"39","author":"Okarvi","year":"2012","journal-title":"Nucl Med Biol"},{"key":"2026102808262949900_ref40","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1535-7163.MCT-11-0764","article-title":"Effect of small-molecule\u2013binding affinity on tumor uptake in vivo: A systematic study using a Pretargeted bispecific antibody","volume":"11","author":"Orcutt","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2026102808262949900_ref41","doi-asserted-by":"publisher","first-page":"e1502","DOI":"10.1002\/wcms.1502","article-title":"The challenge of predicting distal active site mutations in computational enzyme design","volume":"11","author":"Osuna","year":"2021","journal-title":"WIREs Comput Mol Sci"},{"key":"2026102808262949900_ref42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/acsbiomedchemau.2c00008","article-title":"Design and engineering of Miniproteins","volume":"2","author":"O\u017cga","year":"2022","journal-title":"ACS Bio Med Chem Au"},{"key":"2026102808262949900_ref43","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"2026102808262949900_ref44","doi-asserted-by":"crossref","first-page":"12533","DOI":"10.3390\/molecules171112533","article-title":"Chemical synthesis, backbone cyclization and oxidative folding of cystine-knot peptides \u2014 Promising scaffolds for applications in drug design","volume":"17","author":"Reinwarth","year":"2012","journal-title":"Mol"},{"key":"2026102808262949900_ref45","doi-asserted-by":"publisher","first-page":"10608","DOI":"10.1038\/s41598-024-61230-z","article-title":"Development of a new affinity maturation protocol for the construction of an internalizing anti-nucleolin antibody library","volume":"14","author":"Ribeiro","year":"2024","journal-title":"Sci Rep"},{"key":"2026102808262949900_ref46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1126\/science.aan0693","article-title":"Global analysis of protein folding using massively parallel design, synthesis, and testing","volume":"357","author":"Rocklin","year":"2017","journal-title":"Science"},{"key":"2026102808262949900_ref47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102808262949900_ref48","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","article-title":"A modeling analysis of the effects of molecular size and binding affinity on tumor targeting","volume":"8","author":"Schmidt","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2026102808262949900_ref49","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41587-022-01630-6","article-title":"Fresh from the biotech pipeline: Fewer approvals, but biologics gain share","volume":"41","author":"Senior","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026102808262949900_ref50","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026102808262949900_ref51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41698-022-00323-2","article-title":"Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer","volume":"6","author":"Shi","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026102808262949900_ref52","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/cr960065d","article-title":"Phage display","volume":"97","author":"Smith","year":"1997","journal-title":"Chem Rev"},{"key":"2026102808262949900_ref53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1021\/acscombsci.8b00156","article-title":"Cellular-based selections aid yeast-display discovery of genuine cell-binding ligands: Targeting oncology vascular biomarker CD276","volume":"21","author":"Stern","year":"2019","journal-title":"ACS Comb Sci"},{"key":"2026102808262949900_ref54","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/bit.26001","article-title":"Geometry and expression enhance enrichment of functional yeast-displayed ligands via cell panning","volume":"113","author":"Stern","year":"2016","journal-title":"Biotechnol Bioeng"},{"key":"2026102808262949900_ref55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of177Lu-Dotatate for Midgut neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102808262949900_ref56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jtbi.2012.08.034","article-title":"A mechanistic compartmental model for total antibody uptake in tumors","volume":"314","author":"Thurber","year":"2012","journal-title":"J Theor Biol"},{"key":"2026102808262949900_ref57","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1158\/0008-5472.CAN-07-3018","article-title":"Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids","volume":"68","author":"Thurber","year":"2008","journal-title":"Cancer Res"},{"key":"2026102808262949900_ref58","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/d41573-025-00096-w","article-title":"The landscape for radioligand therapies in oncology","volume":"24","author":"To","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026102808262949900_ref59","first-page":"953","article-title":"Tumor targeting using affibody molecules: Interplay of affinity, target expression level, and binding site composition","volume":"53","author":"Tolmachev","year":"2012","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"2026102808262949900_ref60","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1021\/acs.jpcb.6b09973","article-title":"Effects of active site mutations on specificity of nucleobase binding in human DNA polymerase \u03b7","volume":"121","author":"Ucisik","year":"2017","journal-title":"J Phys Chem B"},{"key":"2026102808262949900_ref61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1684226","article-title":"A novel cytotoxic anti-B7-H3 affibody with therapeutic potential in acute myeloid leukemia","volume":"16","author":"Vasilescu","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026102808262949900_ref62","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1021\/jm4011675","article-title":"Hydrocarbon-stapled peptides: Principles, practice, and progress","volume":"57","author":"Walensky","year":"2014","journal-title":"J Med Chem"},{"key":"2026102808262949900_ref63","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1021\/bi0518242","article-title":"Effects of a distal mutation on active site chemistry","volume":"45","author":"Wang","year":"2006","journal-title":"Biochemistry"},{"key":"2026102808262949900_ref64","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"key":"2026102808262949900_ref65","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-12-396962-0.00010-0","article-title":"Practical theoretic guidance for the design of tumor-targeting agents","volume":"503","author":"Wittrup","year":"2012","journal-title":"Methods Enzymol"},{"key":"2026102808262949900_ref66","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nsmb.1793","article-title":"A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain","volume":"17","author":"Wojcik","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"2026102808262949900_ref67","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1021\/acs.biochem.6b01142","article-title":"A gradient of sitewise diversity promotes evolutionary fitness for binder discovery in a three-helix bundle protein scaffold","volume":"56","author":"Woldring","year":"2017","journal-title":"Biochemistry"},{"key":"2026102808262949900_ref68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138956","article-title":"High-throughput ligand discovery reveals a sitewise gradient of diversity in broadly evolved hydrophilic fibronectin domains","volume":"10","author":"Woldring","year":"2015","journal-title":"PLoS One"},{"key":"2026102808262949900_ref69","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","article-title":"B7-H3 negatively modulates CTL-mediated cancer immunity","volume":"24","author":"Yonesaka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026102808262949900_ref70","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: A comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov Oncol"},{"key":"2026102808262949900_ref71","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1158\/0008-5472.CAN-09-2724","article-title":"Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size","volume":"70","author":"Zahnd","year":"2010","journal-title":"Cancer Res"},{"key":"2026102808262949900_ref72","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod Pathol"},{"key":"2026102808262949900_ref73","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.856049","article-title":"Strategies and considerations for improving recombinant antibody production and quality in Chinese hamster ovary cells","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2026102808262949900_ref74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/abt\/tbac029","article-title":"Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics","volume":"6","author":"Zhang","year":"2023","journal-title":"Antib Ther"},{"key":"2026102808262949900_ref75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: An emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"}],"container-title":["Protein Engineering, Design and Selection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/peds\/advance-article-pdf\/doi\/10.1093\/protein\/gzag031\/72357926\/gzag031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/peds\/article-pdf\/doi\/10.1093\/protein\/gzag031\/72357926\/gzag031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/peds\/article-pdf\/doi\/10.1093\/protein\/gzag031\/72357926\/gzag031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:26:35Z","timestamp":1793190395000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/peds\/article\/doi\/10.1093\/protein\/gzag031\/8979312"}},"subtitle":[],"editor":[{"given":"Arne","family":"Skerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":75,"URL":"https:\/\/doi.org\/10.1093\/protein\/gzag031","relation":{},"ISSN":["1741-0126","1741-0134"],"issn-type":[{"value":"1741-0126","type":"print"},{"value":"1741-0134","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"gzag031"}}